These findings indicate that the cell of origin and founding lesions, rather than an accumulation of distinct genomic alterations, prime tumour cells for lineage promiscuity. Moreover, these findings position MPAL in the spectrum of immature leukaemias and provide a genetically informed framework for future clinical trials of potential treatments for MPAL.
Acute leukaemia of ambiguous lineage (ALAL) comprises a collection of high-risk leukaemias defined by immunophenotype, including MPAL and acute undifferentiated leukaemia (AUL). MPAL demonstrates features of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML), while AUL lacks lineage-defining features. MPAL represents 2-3% of cases of childhood acute leukaemia, whereas AUL is rare 1, 2 . Survival rates for children and adults with MPAL are 47-75% and 20-40%, respectively, and there is no consensus regarding the optimal (AML-or ALL-directed) therapeutic regimen [1] [2] [3] . Up to 15% of patients with MPAL have rearrangements of KMT2A (also known as MLL; rearrangements referred to as KMT2Ar) or a BCR-ABL1 fusion gene, but the genetic basis of most cases of MPAL remains unknown. As the lineage 'aberrancy' or 'promiscuity' of T/M MPAL shares features with early T-cell precursor (ETP) ALL 4, 5 , we sought to define the genetic basis of MPAL, to compare its genomic landscape to those of other leukaemia subtypes, and to determine the genetic basis of the intratumoral phenotypic heterogeneity that is characteristic of this disorder.
Article reSeArcH dominance of ALAL (1.6:1), which was diagnosed at similar frequency throughout childhood, except for cases with KMT2Ar, which were common in infants (Supplementary Tables 1, 2 ). The cohort included 49 cases of T/M MPAL, 35 B/M MPAL, 16 KMT2Ar MPAL and 2 BCR-ABL1 MPAL, 8 MPAL not otherwise specified (NOS), and 5 AUL. There was extensive immunophenotypic heterogeneity, with bilineal patterns (multiple immunophenotypic subpopulations), biphenotypic patterns (coexpression of lymphoid and myeloid antigens), or both (Extended Data Fig. 2a-g ). There was no difference in five-year overall survival between T/M MPAL and B/M MPAL (56.7% ± 10.8% (95% confidence interval) and 59.7% ± 11.4%, respectively); outcome for patients with KMT2Ar was poor (five-year overall survival 21.2% ± 10.8%) (Extended Data Fig. 2h-o) .
Genomic alterations were examined by exome (n = 92), transcriptome (n = 95), and/or whole-genome (n = 47) sequencing, and single nucleotide polymorphism (SNP) array analysis (n = 95) (Supplementary  Tables 3, 4) . We identified 158 recurrently altered genes, of which 81 were mutated in at least three cases. Commonly mutated genes included those recurrent in AML, such as FLT3 (n = 31), RUNX1 (n = 15), CUX1 (n = 7) and CEBPA (n = 5); those recurrent in ALL, including CDKN2A or CDKN2B (n = 22), ETV6 (n = 23), and VPREB1 (n = 15); and those recurrent in both AML and ALL, including WT1 (n = 28) and KMT2A (n = 26) (Fig. 1a, Extended Data Figs. 3, 4 and Supplementary Tables 5-13). We analysed associations between genomic alterations and age at diagnosis, sex and disease subtype, and between pathway alterations and outcome (Supplementary Tables 14, 15 and Supplementary Note). We analysed germline samples for potential pathogenic variants in recurrently somatically mutated genes, and identified few putatively deleterious variants 7 (Supplementary Table 16 and Supplementary Note).
Distinct profiles of MPAL subtypes
The three most common subtypes of MPAL (T/M, B/M and KMT2Ar) had distinct patterns of genomic alterations (Fig. 1a -c and Supplementary Table 13 ). As in infant ALL, KMT2Ar MPAL had a low mutation burden (median 1 (range 0-3) copy number alterations (CNAs) and 4 (0-12) single nucleotide variants (SNVs) or insertions/deletions (indels) per case), whereas the mutation burden was higher for T/M MPAL (4.5 (0-35) CNAs, 8 (2-29) SNVs or indels) and B/M MPAL (3.5 (0-29) CNAs, 9 (0-167) SNVs or indels) (Extended Data Fig. 3b ). Alterations in genes encoding transcriptional regulators were detected in 100% of cases of T/M MPAL, with mutually exclusive alterations in WT1, ETV6, RUNX1 and CEBPA in 82% of cases ( Fig. 1b and Extended Data Fig. 5a , b); and in 94% of cases of B/M MPAL, with the B-lineage transcriptional regulators PAX5 and IKZF1 altered in 40% of cases (Fig. 1b) FLT3  JAK3  TCF3  TLX3  TP53  BCL11B  CEBPA  KMT2A  MLLT3  PHF6  EZH2  SETD2  AFF1  CTCF  VPREB1  FBXW7  NOTCH1  NUP214  RPL22  ASXL1  EP300  KMT2D  KDM6A  WT1  IKZF1  EBF1  PAX5  RUNX1  CUX1  RB1  ETV6  ZNF384  CDKN2A/B  CREBBP  CDKN1B  NRAS KRAS PTPN11 Frequency of mutations in the different MPAL subtypes were compared by two-sided Fisher exact tests; **P < 0.001, *0.001 < P < 0.01 (see Supplementary Table 13 for numbers for each group and P values for each gene). #KMT2A alterations were present in all cases in the KMT2Ar subgroup. b, Oncoprint of mutations in transcriptional regulation and cell cycle/apoptosis pathways. ITD, internal tandem duplication; PAM, prediction analysis of microarrays. c, Oncoprint of mutations in signalling pathways. Mutations altering genes involved in transcription and signalling pathways in these subtypes are distinct.
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T/M MPAL (57%) than B/M MPAL (23%) or KMT2Ar MPAL (19%) (Fig. 1c) , and we observed a negative correlation between alterations in FLT3 (43%) and the Ras pathway (33%) in T/M MPAL (P = 0.002) ( Fig. 1c and Supplementary Table 15 ). Ras pathway alterations were common in B/M MPAL (63%, most commonly NRAS and PTPN11). Genes encoding epigenetic regulators were mutated in 69% of cases of T/M MPAL, including inactivating mutations in EZH2 5 (16%) and PHF6 (16%), and in 63% of cases of B/M MPAL, most commonly in MLLT3 (17%), KDM6A (in one-third of ZNF384-rearranged cases), EP300 and CREBBP (Supplementary Table 13) .
Transcriptome sequencing identified chimaeric in-frame fusions in 15 of 40 cases of T/M MPAL: ZEB2-BCL11B (n = 3), ETV6-NCOA2 (n = 2), ETV6-ARNT (n = 2) and single cases of ETV6-FOXO1, ETV6-MAML3, NUP214-ABL1, PICALM-MLLT10 and PCM1-FGFR1 (Supplementary Tables 17-20) . KMT2Ar MPAL had a B/M phenotype in 15 out of 16 cases and a T/M phenotype in one case, and involved AFF1 (also known as AF4) in seven cases, MLLT3 (also known as AF9) in three cases and MLLT1 (also known as ENL) in two cases. KMT2Ar was also found in two of five cases of AUL.
ZNF384 rearrangement in leukaemia
Rearrangement of ZNF384 (ZNF384r) was present in 48% of cases of B/M MPAL, involving TCF3 (n = 8), EP300 (n = 5), TAF15 (n = 1) and CREBBP (n = 1) (Extended Data Fig. 5c ). The chimaeric fusions involved the entire ZNF384 coding region, loss of the C termini of the partner genes, and translation of both wild-type ZNF384 and chimaeric fusion proteins. The mutational burden of ZNF384r B/M MPAL (median of 4 (1-29) CNAs and 8 (3-39) SNVs or indels) was similar to those of other MPAL subtypes (Extended Data Fig. 3c) , with no variation in mutations between immunophenotypic subpopulations in ten cases examined (Extended Data Fig. 5d ). ZNF384r, most commonly with TCF3, is also observed in B cell ALL (B-ALL), in which aberrant expression of myeloid markers that do not fulfil the diagnostic criteria for B/M MPAL is common 8 . The genomic landscape of childhood ZNF384r B-ALL (n = 19) (Supplementary Tables 21, 22 ) was similar to that of ZNF384r MPAL with the exception of KDM6A alterations, which were observed only in ZNF384r MPAL (Fig. 2a) . Analysis of a diverse range of acute leukaemias, including AML (Supplementary  Tables 23, 24 ), showed that the gene expression profiles (GEPs) of ZNF384r B/M MPAL and B-ALL were indistinguishable (Fig. 2b , Extended Data Fig. 5e and Supplementary Table 25 ). Patients with ZNF384r exhibited higher FLT3 expression than those with other types of B/M or T/M MPAL (Extended Data Fig. 5f ). Cases of B/M MPAL that exhibited genomic features of other subtypes of B-ALL, such as hyperdiploidy or a Ph-like GEP, clustered with those subtypes of B-ALL (Fig. 2b) . Gene set enrichment analysis suggested that ZNF384r B/M MPAL was arrested at a more mature stage of development than other types of B/M MPAL (Extended Data Fig. 6a and Supplementary ETV6  VPREB1  TCF3  PAX5  FOXO3  IKZF1  TBL1XR1  ZNF384   NRAS  PTPN11  KRAS  NF1   CDKN2A/B  CDKN1B  RB1  LRP1B   KMT2D  MLLT3  PSIP1  KDM6A  SETD2  AEBP2  SMARCA4 SUZ12 P = 1 P = 0.46 P = 0.67 Mutation frequency across cohorts (%) Tables 26, 27 ). However, compared with B-ALL, ZNF384r leukaemia showed enrichment of stem cell pathways and genes upregulated in ETP-ALL (Extended Data Fig. 6b and Supplementary Tables 27-29). Serial sampling of a case of ZNF384r B/M MPAL showed acquisition of a focal heterozygous IKZF1 deletion at first relapse, and a focal homozygous deletion of CDKN2A and CDKN2B at second relapse, with a shift from a myeloid to a lymphoid immunophenotype. Thus, ZNF384r defines a distinct subtype of acute leukaemia with a variable immunophenotype ranging from B-ALL to B/M MPAL.
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To further investigate the role of ZNF384 rearrangement in leukemogenesis, we expressed haemagglutinin (HA)-tagged ZNF384, TAF15-ZNF384 and TCF3-ZNF384 in mouse Arf −/− pre-B cells 9 (Extended Data Fig. 6c ). Chromatin immunoprecipitation with sequencing (ChIP-seq) identified 2,298 peaks with new or increased binding of the fusion proteins compared to wild-type ZNF384, and 495 peaks with reduced binding (Extended Data Fig. 6d ). Gained or increased peaks contained the core ZNF384 binding motif, and were enriched at promoters of genes important for immune system development and transcriptional regulation (Supplementary Tables 30, 31 Table 33 ). Three cases were Ph-like (EBF1-PDGFRB, IGH-CRLF2 and a case lacking an identified kinase lesion), and two were hyperdiploid. Eight cases were KMT2A-like with HOXA9 deregulation, and six of these had genetic alterations associated with HOXA overexpression: MLLT10 rearrangement (n = 2), SET-NUP214 (n = 2), KMT2A partial tandem duplication and MNX1-ETV6 (n = 1 each).
Similarity between T/M MPAL and ETP-ALL
ETP-ALL exhibits aberrant expression of stem cell and myeloid markers (with the exception of myeloperoxidase, which would classify the disease as AML or MPAL) 10 . ETP-ALL is characterized by mutations in regulators of haematopoietic development, signalling, and chromatin remodelling, and a GEP suggesting the cell of origin to be a haematopoietic stem cell (HSC) or progenitor, rather than a T-cell precursor 5 . Because T/M MPAL and ETP-ALL are defined by a phenotype that includes lymphoid and myeloid features 6, 10 , we hypothesized that they might share molecular features. We compared the genomic features of T/M MPAL with those of childhood T cell ALL (T-ALL; n = 245) 11 , ETP-ALL (n = 19) 11 and AML (n = 197) 12 (Supplementary Tables 34, 35 ). Transcription factor gene alterations were common in each but varied between subtypes (Extended Data Fig. 6g ). The core transcription factors driving T-ALL (TAL1, TAL2, TLX1, TLX3, LMO1, LMO2, NKX2-1, HOXA10 and LYL1) were less frequently altered in T/M MPAL and ETP-ALL (63% versus 16% and 26%, respectively; P < 0.001). Alterations that deregulated TAL1, which were present in 31% of cases of T-ALL, were never observed in T/M MPAL, including the 15 cases for which whole-genome sequencing data were examined for noncoding enhancer mutations 13 . Other alterations that are common in T-ALL, such as MYB amplification, LEF1 deletion, CDKN2A and CDKN2B deletions, and amplification of the NOTCH1-driven MYC enhancer, were rare in T/M MPAL and ETP-ALL. By contrast, WT1 alterations were common in T/M MPAL (41%) and ETP-ALL (42%), but not in T-ALL (9%; P < 0.001). Alterations of CEBPA and CUX1 were common in T/M MPAL but not ETP-ALL or T-ALL. Conversely, NOTCH1 mutations were uncommon in T/M MPAL and AML. Signalling pathway mutations were also associated with specific subtypes, with Ras and JAK-STAT pathway mutations being common in T/M MPAL and ETP-ALL, and phosphotidylinositol 3-kinase (PI3K) signalling pathway mutations being common in T-ALL (Extended Data Fig. 6h ). Several genes were mutated at similar frequencies in T/M MPAL and ETP-ALL, including ETV6, EZH2, WT1 and FLT3 (Fig. 2c) , and the GEPs of T/M MPAL and ETP-ALL were similar (Fig. 2b) . Thus, T/M MPAL and ETP-ALL are similar entities in the spectrum of immature leukaemias.
Analysis of intratumoral variegation
Elucidating whether the intra-sample immunophenotypic heterogeneity is determined by genetic variegation or by genomic priming of a haematopoietic progenitor has important implications for therapy. Accordingly, we sequenced 2-4 subpopulations from 50 cases of MPAL (Supplementary Table 36 ). In 41 cases, the non-silent mutations were present in each separate population (Fig. 3a, b and Extended Data Fig. 7a ). In nine cases, multiple mutations were detected CD33-PE-Cy7 MPO-FITC CD34-PerCP-Cy5.5
CD7-PE-Cy7
Scale Variant allele frequency 0.0 0.5 Table 36 ), consistent with previous studies of diagnosis and relapse pairs showing frequent subclonal signalling alterations 14 . By contrast, mutations in the most commonly altered transcription factor in T/M MPAL, WT1, were consistently present in the major clone in each case. These observations support the notion that transcription factor gene alterations arise early in leukemogenesis, and alterations that drive signalling alterations are secondary events.
Similarly, analysis of the DNA methylation profiles of 27 cases of MPAL (11 with multiple subpopulations), 74 non-MPAL leukaemias and 17 normal progenitor samples showed distinct methylation profiles between leukaemia subtypes, but not between MPAL subclones (Extended Data Fig. 7b -e and Supplementary Table 37 ). Thus, cytosine methylation does not drive immunophenotypic heterogeneity in MPAL.
Phenotypic plasticity of MPAL
To further examine the basis of lineage plasticity in MPAL, we used xenograft models in which immunophenotypic subpopulations were purified and transplanted into immunocompromised NOD/SCID/ IL2Rγ-null-3/GM/SF (NSG-SGM3) mice. Sorted subpopulations of cells from a patient with T/M MPAL (Fig. 3c and Extended Data Fig. 8a ), the ZNF384r B/M JIH-5 cell line 15 (Extended Data Fig. 8b,  c) , and a patient with KMT2Ar MPAL (Extended Data Fig. 8d ), when transplanted into multiple independent NSG-SGM3 mice, propagated the immunophenotypic diversity of the primary samples. Moreover, we observed a phenotype shift in a sample from a patient with T/M MPAL during passaging of the bulk tumour sample, with engraftment of either a B/M or T/M leukemia phenotype (Extended Data Fig. 8e-h ). These data demonstrate the multilineage potential of phenotypic subpopulations in MPAL, and phenotypic evolution even in the absence of therapeutic pressure.
Collectively, our genomic data and in vivo lineage plasticity data suggest that intra-sample lineage diversification in MPAL is driven by constellations of genomic alterations acquired in a haematopoietic stem or progenitor cell with multilineage potential. To test this idea, we purified progenitor cell and blast populations and normal mature lymphocytes from samples from a patient with ZNF384r B/M MPAL and two patients with WT1-altered T/M MPAL ( Fig. 4a and Extended Data Fig. 9a, b) . Alterations identified in the unfractionated samples (for example, TCF3-ZNF384 and mutations in MYCN, NTSD2 and DNAH17 in the ZNF384r sample) were identified in the purified blast populations but not in non-leukaemic T or natural killer (NK) cells. Each alteration was also present in multiple haematopoietic progenitor populations with myeloid and lymphoid potential, and a subset of HSCs (Fig. 4b and Extended Data Fig. 9c ). Analogous results were detected in two cases of T/M MPAL with WT1 alterations (data not shown); these contrast with Ph-like B-ALL, in which founding lesions are detectable in a primitive progenitor with the capacity for myelo-lymphoid differentiation, but not in HSCs 16 . These data support the notion that mutations are acquired in a HSC that is primed for lineage aberrancy.
To gain further insight into the relative roles of founding genomic lesions, acquired genetic alterations and the role of therapy in dictating MPAL phenotype, we analysed sequential samples obtained at initial diagnosis and disease recurrence in nine patients. The immunophenotypes of five cases (three T/M MPAL, one B/M MPAL, and one MPAL NOS with T/B phenotype) were stable from diagnosis and relapse, but changed in four cases. Two were ALL (one B-ALL, one ETP-ALL) at diagnosis and relapsed as MPAL, and two were MPAL at diagnosis (one T/M, one B/M) and subsequently relapsed as AML and ALL, respectively (Extended Data Fig. 10 ). In the five cases with immunophenotypic stability, mutations in the predominant clone were lost (PTPN11, CCND3, NOTCH1, and RPL22) or emerged (TP53, IKZF1, NF1, NCOR1, and SUZ12). Despite this genomic evolution, the lineage ambiguity remained, further supporting the notion that MPAL leukaemia-initiating cells are primed for multi-lineage potential. In all four cases with phenotype shifts, the initial therapy correlated with the type of phenotype shift: patients who received ALL-directed therapy relapsed with myeloid leukaemia and one patient who received AML-directed therapy relapsed with lymphoid leukaemia. In two cases, immunophenotype at relapse was also correlated with a mutation characteristic of leukaemia subtype: CEBPA for AML and CDKN2A or CDKN2B for B-ALL. Together, these nine cases with serial samples support the theory that early genomic lesions prime progenitors for lineage aberrancy, which may remain stable or change over time, and Article reSeArcH that phenotype is influenced by therapeutic pressure and/or genomic evolution.
Discussion
This study provides a comprehensive genomic analysis of paediatric MPAL, providing insights into the genomic relationships between immunophenotypically defined subtypes of acute leukaemia. We propose an update to the WHO classification of acute leukaemia that includes new subtypes of ZNF384-rearranged acute leukaemia (either B-ALL or MPAL), WT1-mutant T/M MPAL, and Ph-like B/M MPAL (Extended Data Fig. 1c) .
The ALL-like genomic landscape of B/M MPAL and the similarity in genomic alterations between ZNF384r B/M MPAL and B-ALL supports the use of ALL-directed therapy for patients with B/M MPAL. Furthermore, the overexpression of FLT3 and responsiveness to FLT3 inhibition in ZNF384 leukaemia 17 suggest that such targeted therapy should be considered in this form of leukaemia. Non-ZNF384r cases of B/M MPAL should be carefully evaluated for other kinase-activating alterations that may be amenable to kinase inhibition, as shown in Ph-like ALL 18 . Our data show that ETP-ALL 5 and T/M MPAL are genomically and epigenomically similar, and suggest that FLT3 and/or JAK inhibition should be evaluated further 4 . T/M MPAL exhibits infrequent alteration of core T-ALL transcription factor genes and few mutations in CDKN2A, CDKN2B, NOTCH1 and FBXW7; frequent FLT3-activating mutations; and a GEP that overlaps with that of AML, consistent with the notion that the pathogenesis of T/M MPAL is distinct from that of T-ALL. However, contemporary paediatric ALL trials have demonstrated remarkable success in treating ETP-ALL, which is similar to T/M MPAL, so ALL-directed therapy may also be appropriate for T/M MPAL 19 . In contrast to the notion that subclonal genomic variation drives clonal evolution during disease progression in ALL 14 , our analysis of phenotypically distinct subpopulations within individual patients with MPAL revealed that mutational variegation did not determine phenotypic diversification. Rather, the common genomic features of ZNF384r B-ALL and MPAL, limited mutational variegation between subclones, multi-lineage potential of subclones in xenograft models, lineage plasticity in serial patient samples, and identification of leukaemiainitiating alterations in early haematopoietic progenitors indicate that the ambiguous phenotype of MPAL is the result of the acquisition of alterations in immature haematopoietic progenitors (Fig. 4c, d ). These data also support a model of haematopoiesis in which progenitors retaining multilineage potential undergo terminal differentiation into a single lineage only relatively late in haematopoiesis 20 . By demonstrating the genomic similarity of phenotypically distinct malignant populations, and by identifying the potential clinical importance of ZNF384 fusions, these results emphasize the limitations of morphology and immunophenotype alone in diagnostic evaluation. As has been demonstrated in AML, ETP-ALL, myelodysplastic syndrome, and Ph-like ALL 5, 11, 18, 21, 22 , accurate MPAL sub-classification requires careful genomic analysis to optimally guide diagnosis, risk-stratification and tailoring of therapy. Together, these findings have implications for disease classification and therapeutic decisions, while also clarifying the pathogenesis of this high-risk subtype of acute leukaemia.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0436-0. Supplementary Tables 2-4 ) using whole-exome sequencing (WES) or whole-genome sequencing (WGS), transcriptome sequencing (RNA-seq), SNP microarray, and methylation array analysis. Samples collected on tumour banking protocols were used. Samples were not prospectively collected. The study was approved by the SJCRH Institutional Review Board.
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Tissue. Non-tumour DNA was extracted from remission bone marrow or peripheral blood samples, flow-sorted normal lymphocytes, or cultured fibroblasts using phenol-chloroform organic extraction. Tumour DNA was extracted using phenolchloroform organic extraction. Tumour RNA was extracted using a TRIzol (Life Technologies). WGS, WES and transcriptome sequencing. WGS for 44 cases and RNA-seq for 45 cases were performed by the British Columbia Cancer Agency's Michael Smith Genome Sciences Centre (BCGSC); WGS for 3 cases, WES for 92 cases and RNAseq for 77 cases were performed at SJCRH. For WGS at BCGSC, methods for DNA preparation, sequencing, and quality control are available at https://ocg.cancer.gov/ programs/target/target-methods. For WES at SJCRH, library construction used DNA tagmentation (fragmentation and adaptor attachment) performed using the reagent provided in the Illumina Nextera rapid exome kit, and was performed using the Caliper Biosciences (Perking Elmer) Sciclone G3. First-round PCR (10 cycles) was performed using Illumina Nextera kit reagents, and clean-up steps employ BC/ Agencourt AMPure XP beads. Target capture used Illumina Nextera rapid capture exome kit and supplied hybridization and associated reagents. The pre-hybridization pool size was 12 samples, and second round PCR (10 cycles) performed with Nextera kit reagents. Library quality control was performed using a Victor fluorescence plate reader with Quant-it dsDNA reagents for pre-pool quantification, and Agilent Bio-analyzer 2200 for final library quantification. Paired-end sequencing was performed using Illumina HiSeq 2500 with read length 100 bp.
Methods for RNA preparation, sequencing, and quality control at BCGSC are available at https://ocg.cancer.gov/programs/target/target-methods. At SJCRH, total RNA quality and quantity were assessed on Agilent RNA6000 chips (Agilent Technologies) and Qubit (Life Technologies). RNA-seq libraries were prepared from 500 ng of total RNA for each sample following Illumina RNA-seq protocols, including DNase treatment and phenol purification, cDNA conversion, fragmentation by Covaris Ultrasonicator, end repair, deoxyadenosine tailing, adaptor ligation and PCR amplification (ten cycles). Libraries with a 10 pM concentration were clustered on an Illumina cBot, and each flow cell was loaded onto a HiSeq instrument for sequencing using the Illumina 2×100 bp sequencing kit. RNA-seq was not performed on flow-sorted subpopulations due to the deleterious effects on RNA integrity of cellular fixation/permeabilization performed to enable staining for intracellular markers. Sequencing read alignment. Paired-end WGS and WES data were aligned to the human reference genome GRCh37 by BWA 23 (version 0.7.12). Samtools 24 (version 1.3.1) was used to generate chromosomal coordinate-sorted and indexed BAM files, and then the Picard (http://broadinstitute.github.io/picard/, version 1.129) MarkDuplicates module was used for marking PCR duplication. Afterwards, the reads were realigned around potential indel regions by GATK 25 (version 3.5) IndelRealigner module following the recommended pipeline. Sequencing depth and coverage was evaluated based on coding regions defined by refSeq genes from UCSC, with the length around 34 Mb. SNV/indel calling and filter workflow. The GATK UnifiedGenotyper module was used to identify SNVs and indels from leukaemia and germline samples, which were filtered by a homemade pipeline, excluding: 1) reported common SNPs/ indels from UCSC dbSNP v142; 2) germline mutations detected from matched germline control samples. All the non-silent SNVs/indels yield from the filtering pipeline were manually reviewed and only the highly reliable somatic ones were reported. Meanwhile, adjacent nucleotide changes on the same allele were merged into a single mutation. For patients with flow-sorted subpopulations of sequenced leukaemia cells, the mutation calling for each population was performed de novo.
Mutations detected from some/one of the samples were checked across the other samples from the same patient. In these cases, we applied a threshold of at least 3 mutant allele reads and VAF of at least 1% to report a mutation. For cases without germline samples, a germline sample was picked with highest sequence depth as a pseudo-germline sample to run through the filtering pipeline. In cases in which flow-sorted subpopulations were sequenced, WES or WGS of the unfractionated samples were not performed. Structure variant detection. Structural variants in the tumours were identified by CREST 26 using the tumour vs germline mode, with pseudo-germline data applied for tumours without germline samples. Candidate variants were manually reviewed and the mapping uniqueness was re-evaluated by running BLAT 27 mapping and the confident calls were considered as the final structural variant set. RNA-seq data analysis for patient samples. Paired-end reads were mapped to the GRCh37 human genome reference by STAR 28 (version 2.5.1b) through the recommended two pass mapping pipeline with default parameters and the Picard MarkDuplicates module was used to mark the duplication rate. Gene annotation files were downloaded from Ensembl (http://www.ensembl.org/) and used for STAR mapping and subsequent gene expression level evaluation. CICERO 18 and FusionCatcher 29 were used to detect fusions from mapped BAM files and raw FASTQ files, respectively. The reported fusion contigs were remapped by BLAT to check the reliability of mapping quality, the breakpoints were manually reviewed from the aligned reads and the highly confident fusions were reported. To evaluate GEP, reads count for annotated genes was called by HTSeq 30 (version 0.6.0) and processed by DESeq2 R package 31 to normalize gene expression into regularized log 2 values (rlog). Six cases without DNA-sequence data were screened for SNVs/ indels by following the GATK best practices for variant calling on RNAseq (https:// gatkforums.broadinstitute.org/gatk/discussion/3892/the-gatk-best-practices-forvariant-calling-on-rnaseq-in-full-detail). The filtering process is the same as for germline variant analysis described below. Gene set enrichment and pathway analysis. Read counts from RNA-seq data were imported to DESeq2 32 R package for differential gene expression analysis. To perform gene set enrichment analysis (GSEA) 33 , all the genes were ranked according to the fold-change and significance from differential analysis. GSEA was performed using mSigDB C2 genes and curated gene sets from in-house analyses. Cell line transcriptome analysis. Total RNA was isolated from green fluorescent protein (GFP)-positive, sorted cells using the RNeasy Mini Kit (Qiagen). RNA quality was checked using 2100 Bioanalyzer RNA 6000 Nanoassay (Agilent) or LabChip RNA Pico Sensitivity assay (PerkinElmer) before library generation. Libraries were prepared from total RNA with the TruSeq Stranded Total RNA Library Prep Kit (Illumina). Libraries were quantified using the Quant-iT PicoGreen dsDNA assay (Life Technologies) Kapa Library Quantification kit (Kapa Biosystems) or low pass sequencing on a MiSeq Nano v2 run (Illumina). One hundred cycle paired end sequencing was performed on an Illumina HiSeq 2500, HiSeq 4000, or NovaSeq 6000. RNA isolation, library preparation, and sequencing were performed on three biological replicates. RNA-seq data were mapped as described previously 18 and HTSeq 30 (version 0.6.1p1) were used to get gene-level count and estimated FPKM based on GENCODE (vM9) 34 . Voom 35 was used for gene differential expression analysis after trimmed mean normalization. CNA and loss of heterozygosity (LOH). DNA from leukaemia and matched germline samples was prepared for hybridization to Illumina Infinium Omni2.5 Exome-8 SNP arrays according to the manufacturer's protocol. The raw intensity data (*.idat files) were analysed by the Genotyping Module of Illumina Genome Studio software version 2.0.3. Normalized log R ratio (LRR) and B allele frequency (BAF) for all the available probes in each sample were extracted. For ZNF384r B-ALL cases, data acquired from Affymetrix Genome-Wide Human SNP Array 6.0 were also converted to LRR and BAF values following the pipeline described by PennCNV 36 (http://penncnv.openbioinformatics.org/en/latest/user-guide/affy/). With the input of LRR and BAF, somatic genomic alterations in paired or unpaired samples were called by OncoSNP version 2.1 37 . To verify the reliability of CNAs and LOHs, all the reported alterations were plotted based on LRR and BAF in ShinyCNV (https://github.com/gzhmat/ShinyCNV) and visually checked 38 . Only somatic alterations meeting the criteria proposed by OncoSNP and PennCNV were kept for further analysis. DNA methylation assay and data analysis. We examined DNA methylation profiles in 27 MPAL cases (11 with 2-4 subpopulations), 15 AML, 29 B-ALL, 30 T-ALL, and 17 normal lymphocyte samples from 4 healthy donors. Raw data from the Infinium MethylationEPIC BeadChip Kit (Illumina Inc.) were analysed using the ChAMP 39 R package. In general, the raw *.idat files were imported through 'minfi' method 40 and then the following filters were applied to exclude the probes: (1) with detection P value above 0.01 in one or more samples; (2) with beadcount <3 in at least 5% of samples; (3) as non-CpG probes; (4) identified as SNPs 41 ; (5) aligned to multiple locations 42 ; and (6) on the X or Y chromosome. After filtering, 'BMIQ' normalization from ChAMP package was used as the author suggested to calculate methylation beta values. Batch effect was observed by the singular Article reSeArcH value decomposition method 43 and adjusted by ComBat normalization method 44 . The 5,000 probes with the highest median absolute deviations (MAD) were used to perform clustering with a two-dimensional t-distributed stochastic neighbour embedding (t-SNE) plot and heat map 45 . Table 19 ) using the listed probes, in Carnoy's fixative as previously described 46 . BAC clones (Supplementary Table 20) were labelled with rhodamine or fluorescein isothiocyanate. At least 100 interphase nuclei were scored per case. Flow cytometry analysis and flow cytometry-assisted cell sorting. Flow cytometry analysis and sorting were performed on an 18-colour Aria cell sorter (BD Biosciences). When available, cryopreserved samples were analysed by flow cytometry using CD45-APC-H7 (BD 560178), cytoplasmic CD3-PE (BD 347347), CD34-PerCP Cy5.5 (BD 347203), CD19-APC (BD 340437), cytoplasmic MPO-FITC (Dako F071401-1) , and CD33-PE-Cy7 (BD 333946). Depending on the phenotypes reported from the outside institutions, samples were additionally analysed using cytoplasmic CD79a-APC (BD 551134), CD22-BV421 (BD 563940), CD64-PerCP-Cy5.5 (BD 561194), CD14-PE-Cy7 (BD 560919), cytoplasmic lysosome-FITC (Life Technologies GIC207), and CD11c-APC (BD 560895). For 50 cases, leukaemic cells in the CD45 and side scatter-defined blast gate were sorted into subpopulations based upon cytoplasmic MPO and either CD19 or cytoplasmic CD3. When feasible, normal lymphocytes were sorted using side scatter, CD45 lymphocyte gate and secondarily using CD19 and cytoplasmic CD3 to collect normal B cells in T/M MPAL cases and normal T cells in B/M, KMT2Ar, AUL, or NOS cases. Fibroblast cultures. Bone marrow cells were cultured in change medium (Irvine scientific, T105), which was changed every 5 days. Cells were collected for DNA extraction when the fibroblasts became at least 70% confluent. Table 34 ) and publicly available data can be found at https://ocg.cancer.gov/programs/target 12 . Nineteen ETP-ALL and 245 non-ETP T-ALL cases from the COG were sequenced through the NCI TARGET project using WES and total stranded RNA-seq for SNV, indel, CNA and SV calls, fusion detection and GEP comparison 11 (Supplementary Table 35 ). A cohort of AML, B-ALL 16, 18, [47] [48] [49] (n = 161), T-ALL 11 (n = 50), ETP-ALL 11 (n = 19) and 12 normal lymphocyte samples was used for GEP comparison (Supplementary Table 23 ). The AML samples were sequenced at SJCRH and had stranded total RNA-seq for GEP comparisons. This cohort consists of five cases with core binding factor translocations (three with RUNX1-RUNX1T1, two with CBFB-MYH11), five cases with normal karyotype, and five cases with KMT2Ar). B-ALL subtyping based on GEP. RNA-seq data analysis for patient samples is described above. As many B-ALL subtypes defined by single chromosomal aneuploidy or rearrangement may be clustered based on their GEP 48, [50] [51] [52] [53] [54] , a subtype predication model was trained by prediction analysis of microarrays (PAM) 55 using a cohort of 322 B-ALL samples from our previous studies 18, 48, 49 , which consists of eight canonical B-ALL subtypes: DUX4 rearrangement (n = 40), ETV6-RUNX1 (n = 42), high hyperdiploidy (n = 45), MEF2D rearrangement (n = 29), KMT2Ar (n = 44), TCF3-PBX1 (n = 40), BCR-ABL1 (n = 42) and ZNF384 rearrangement (n = 40). The PAM model was trained on 200 different thresholds with tenfold cross-validation. On the basis of the trained model and cross-validation result, 100 thresholds (control the selected feature genes from 5,000 to 50) were tested on the training data set to determine the optimal threshold range for each subtype. Then the trained model was applied to the MPAL samples to determine their similarity to each B-ALL subtype for 100 rounds, using evenly distributed thresholds across the optimal threshold range for each B-ALL subtype, and the average score was taken as the consensus likelihood score for that subtype (Supplementary Table 33 ). Germline variant analysis. Germline variants were called by GATK 56 UnifiedGenotyper from the BAM files of all the germline samples, and then the following filters were applied to identify potential pathogenic germline variants: (1) exclusion of variants with fewer than five mutant reads support or a VAF below 20%; (2) exclusion of variants in common SNP database (VAF greater than 0.1% in population according to dbSNP 142); (3) exclusion of SNPs with at least ten occurrences observed in dbSNP 142 but not reported as somatic mutations in the COSMIC V80 database; (4) exclusion of variants in genes with fewer than three somatic mutations in MPAL cohort; (5) annotation of variants using the Variant Effect Predictor (VEP; https://useast.ensembl.org/Tools/VEP) and then exclusion of variants predicted as benign by any of the predictors (SIFT, PolyPhen, Condel). The remaining mutations were manually reviewed and obvious mapping artefacts were excluded. Mutations were then assessed according to ACMG recommendations 7 . Lentiviral transduction of cells. cDNAs encoding ZNF384 (XM_017018949), TAF15 (NM_139215)-ZNF384 (exon 6-exon 3), and TCF3 (NM_003200)-ZNF384 (exon 13-exon 5) were amplified from human leukaemic cell RNA and cloned with a C-terminal HA epitope tag (added using the QuikChange II XL Site-Directed Mutagenesis Kit, Agilent) into the CL20c-MSCV-IRES-GFP vector. Vectors were packaged into lentiviral particles by transient transfection of HEK293T cells with a triple plasmid (pHDMG, pCAG HIV, pCAG RTR) system. Lentiviral supernatants were used to infect interleukin-7 (IL-7)-dependent Arf −/− pre-B cells on RetroNectin (Takara Bio) for 48 h before sorting for GFP + cells (BD FACSAria, BD Biosciences). Chromatin immunoprecipitation and sequencing. ChIP assays were carried out as described previously 49 . In brief, 2 × 10 7 GFP-positive cells were incubated for 10 min in 1% formaldehyde in phosphate-buffered saline (PBS) at room temperature, quenched by the addition of 1/10 volume of 2 M glycine. Cells were then washed three times with cold PBS containing proteinase inhibitors and lysed on ice for 10 min in lysis buffer (50 mM HEPES, pH 7.9, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100). Chromatin was washed twice in washing buffer (10 mM Tris-HCl, pH 8, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) and then twice in shearing buffer (0.1% SDS, 10 mM Tris-HCl, pH 8, 1 mM EDTA) before resuspension in 1 ml shearing buffer. Chromatin was sonicated in 1-ml AFA millitubes using a Covaris E210 instrument for 15 min at 5% duty cycle, intensity 4, 200 cycles per burst at 4 °C. Sheared chromatin was spun down for 10 min at 13,200g at 4 °C, and the supernatant was mixed with an equal amount of ChIP dilution buffer (0.1% SDS, 30 mM Tris-HCl, pH 8, 1 mM EDTA, 300 mM NaCl, 2% Triton X-100) before ChIP experiments. Immunoprecipitation was performed with an antibody to HA (ab9110, Abcam) and a normal rabbit IgG control (Santa Cruz Biotechnology) using 2 μg antibody per ChIP. This experiment was performed with three biological replicates.
Fusion validation. Fluorescence in situ hybridization (FISH) was performed to confirm fusions in 22 cases (Supplementary

Comparison cohorts. Comparison cohorts of AML, ETP-ALL, non-ETP T-ALL, and B-ALL were examined. A cohort of 197 paediatric patients with AML from the COG with WGS performed though the NCI TARGET initiative was used as comparison (Supplementary
To prepare ChIP-seq libraries, 10 ng of ChIP DNA was end repaired and adaptor ligation was performed using the Next ChIP-Seq Library Prep Reagent Set for Illumina (New England BioLabs). Libraries were purified after 14 rounds of PCR amplification with Q5 DNA Hot-Start polymerase (New England BioLabs). Each ChIP-seq library underwent 50-cycle single-end sequencing using TruSeq SBS kit v3 on an Illumina HiSeq 2000.
Alignment and quality control were performed as described 57 . Fifty base pair single-end reads were mapped to mouse genome mm9 (MGSCv37) with BWA 23 (version 0.7.12-r1039), duplicated reads were marked with Picard and only unique mapped reads extracted by Samtools 24 (version 1.2) were kept for analysis. We extended each read to estimated fragment size by SPP 58 (version 1.1) and generated bigwig files, scaling the track by normalizing to 15 million unique mapped reads.
For differential binding analysis, peaks were called with MACS2 59 (version 2.0.10.20131216, parameter '-nomodel-extsize FRAGMENT SIZE' and fragment size was estimated as described above by SPP 58 (version 1.1) twice for each sample. High confidence peaks used a cutoff of FDR-corrected P value of 0.05 and low confidence peaks used a cutoff of FDR-corrected P < 0.5. Peaks from replicates were merged only if called as high confidence peaks in one sample and called as at least low confidence peaks in other replicates. Finally, peaks from wild-type ZNF384 and ZNF384 fusions were merged as a reference peak set. For each sample, we first extend read to the estimated fragment size, then we counted the extended reads number overlapping the reference peaks by BEDTools (version 2.24.0) 60 . Following PCA analysis, which showed a clear separation of wild-type and fusion ChIP-seq data, Voom 35 was used to examine differences in strength of binding between wild type and fusion after trimmed mean normalization. Common differential binding sites (q value less than 0.05 and fold change greater than 1) between TAF15-ZNF384 versus wild-type proteins and TCF3-ZNF384 versus wild-type proteins were used for visualization. Real-time PCR (ΔC t method) was employed to validate ChIP-seq results. Differential binding sites were annotated to genes if their promoter (transcription start site ± 2 kb) overlapped the binding sites. GSEA 33 was used to compare ChIP-seq peak lists to the GEP of cell lines expressing ZNF384 fusions. Statistical analysis. The correlation between sex, disease subtype (WHO 2016 criteria, our proposed update to classficiation of ALAL, or fusion presence/absence) and single gene mutation or pathway mutations was assessed using the two-sided Fisher exact test. The correlation between subtypes and age categories was assessed using the two-sided Fisher exact test. The correlation between age as a continuous variable and single gene mutation or pathway mutations was assessed using the non-parametric Wilcoxon rank-sum test. The Kaplan-Meier method was used to estimate the survival function and overall survival distributions were compared with log-rank tests. GraphPad Prism (version 7.04) and SAS (version 9.4) were used for statistical analysis. 
Article reSeArcH
anti-CD38-PE-Cy7 (335790), anti-CD10-BV421 (562902), anti-CD7-V450 (642916), anti-CD45-AlexaFluor 700 (Thermo Fisher Scientific MHCD4529), anti-CD34-APC-Cy7 (Biolegend, custom-made, CD34 clone 581), anti-CD33-APC (340680) and anti-CD19-BV605 (562653). For sorting of mature cells and leukaemic blasts, mononuclear cells from bone marrow of patient SJMPAL040028 were stained with the following antibodies: anti-CD45-AlexaFluor 700 (Thermo Fisher Scientific MHCD4529), anti-CD19-BV605 (562653), anti-CD10-BV421 (562902), anti-CD33-PE-Cy7 (333946), CD3-PE (347347) and anti-CD56-AlexaFluor 647 (557711). For all samples, cells (from 5 to 1,000) per fraction were sorted on a BD FACS Aria in a 96-well plate. As previously published 16 Genomic analysis of sorted subpopulations. Upon completion of WGA, DNA was subjected to PCR amplification using primers specific for the TCF3-ZNF384 fusion or for additional genetic alterations, including SNVs/indels in NDST2, DNAH17 and MYCN, identified from analysis of WES data. Primers were designed to flank the fusion breakpoint or the identified variants using Primer3 (TCF3-ZNF384 forward: 5′-GAGGAGGACCAGGAGAGATGG-3′ and TCF3-ZNF384 reverse: 5′-ATCAGGCAAGGCTTCCTAAAAG-3′; NDST2 forward: 5′-ATAGGTACACTCCCTGCCTTTCC-3′ and NDST2 reverse: 5′-ACCCCAAACCTTGACCCTTTT-3′; DNAH17 forward: 5′-CTCCTC TTTGGGAACCCTCTG-3′ and DNAH17 reverse: 5′-GAAAAGGCTTG TGCTGACATCTT-3′; MYCN forward: 5′-GTGTCTGTCGGTTGCAGTGTT-3′ and MYCN reverse: 5′-AGCTCGTT CTCAAGCAGCATCT-3′). PCR was performed using KAPA2G Fast HotStart Ready Mix (07961260001, Kapa Biosystems) according to the manufacturer's instructions with 10 μM each primer and 2 μl diluted (1:100) WGA DNA. All amplicons were quality checked on a 1.5% agarose gel and purified using Wizard SV Gel and PCR Clean-Up System (A9282, Preprotech). Sequences were verified by Sanger sequencing. The sequenced amplicon was aligned to a reference fusion sequence generated from National Center for Biotechnology Information and to the contigs obtained from RNA-seq in case of TCF3-ZNF384 fusion. The results were analysed using CLC Main Workbench (Qiagen). Xenografts. Mice were housed in an American Association of Laboratory Animal Care (AALAC)-accredited facility and were treated according to Institutional Animal Care and Use Committee (IACUC) protocols approved by SJCRH in accordance with NIH guidelines. JIH-5-derived xenograft. The JIH-5 cell line 15 was obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). Cells were thawed and cultured according to DSMZ's instructions (https://www.dsmz.de/catalogues/ details/culture/ACC-788.html). Immunophenotypic and genomic analyses (RNAseq) were performed prior transplant assays. Short tandem repeat (STR) DNA analysis was performed for cell line authentication (Supplementary Table 38) , showing concordance with DSMZ STR analysis. STR analysis was performed using the The PowerPlex 16 HS System (Promega) which allows co-amplification and three-colour (blue or fluorescein-labelled, black or TMR-labelled, and green or JOE-labelled) detection of sixteen loci (fifteen STR loci and Amelogenin), including Penta E, D18S51, D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Amelogenin, Penta D, CSF1PO, D16S539, D7S820, D13S317 and D5S818. All sixteen loci were amplified simultaneously in a single tube and analysed in a single injection. . The number of cells that was transplanted and the total number of mice transplanted per subpopulation depended on the number of viable cells that were available, but ranged from 0.2 to 0.6 million cells and 1 to 5 mice, respectively. Engraftment was monitored by weekly measurement of bioluminescence (region of interest (ROI)) at Xenogen IVIS-200 (PerkinElmer). ROI measurements and total fluxes (photons/second, p/s) were recorded and analysed by the Living Imaging v.4.4 software (Caliper Life Sciences). When total fluxes were at least 1 × 10 8 in all animals, mice were euthanized, and blood, bone marrow, and spleen samples were analysed to determine the leukaemia phenotype, using morphology, flow cytometry, and histopathologic analysis. MPAL patient-derived xenografts (PDX). MPAL PDX were established from three patients (SJMAPL011911, SJMAPL014124 and SJMAPL040036). Frozen mononuclear cells from bone marrow at diagnosis were thawed and used as bulk (SJMAPL040036) or flow-sorted in transplantation assays. Cells from SJMAPL011911 were stained with the following human-specific antibodies: anti-CD45-APC-H7 (BD, 641399), CD34-PerCP-Cy5.5 (BD, 347203), anti-CD33-PE-Cy7 (BD, 3339460) and anti-CD7-PE-Cy7 (BD, 544019 62 mice that were sublethally irradiated (250 RAD) 6-24 h before transplantation. The number of cells that was transplanted and the total number of mice transplanted per sample depended on the number of viable cells that were available, but ranged from 0.2 to 0.6 million cells and 1 to 5 mice, respectively. Human leukaemia engraftment was monitored in peripheral blood by performing serial retro-orbital bleeds one month after injections and monthly thereafter. Peripheral blood samples were analysed by flow cytometry for human CD45
+ cells and when CD45 + cells were >5%, mice were euthanized, and blood, bone marrow, and spleen samples were analysed to determine the leukaemia phenotype, using morphology, flow cytometry, and histopathologic analysis. Immunohistochemistry (IHC) was performed on formalin-fixed paraffin-embedded tissues sectioned at 4 μm. Assays for CD19 (AbDserotec, MCA2454T; 1:100), CD34 (Ventana, 790-2927; ready to use), CD45 (Ventana, 760-2505; ready to use) and myeloperoxidase (MPO, DAKO A398; 1:500) were performed on the Ventana Benchmark. The assay for CD33 (Leica Biosystems, NCL-L-CD33; 1:200) was performed on the Dako Omnis. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. Sequencing, SNP, and methylation data are available at the NCI Genomics Data Commons (GDC, gdc.cancer.giv) and analysed data may be accessed at the TARGET website at https://ocg.cancer.gov/programs/target/data-matrix or https://gdc.cancer.gov/about-data/publications/TARGET-ALAL-2018. Mouse RNA-seq and ChIP-seq data have been deposited in the GEO database under accession ID GSE112561. For T-ALL and ETP-ALL, RNA sequencing for comparison comprised previously published data 11 . B-ALL RNAsequencing data for comparison comprised previously published data and recently sequenced samples that will be made available through St Jude's Children's Research Hospital 11, 18, 48, 49, 63 . T-ALL, ETP-ALL, and AML data for mutation comparison comprised previously published data 11, 12 . The genomic landscape reported in this study can be explored at the St. Jude PeCan Data Portal, http://pecan.stjude.org/ proteinpaint/study/pediatric-mpal. 
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Variant Effect Predictor (VEP https://useast.ensembl.org/Tools/VEP) SPP (version 1. All studies must disclose on these points even when the disclosure is negative.
Sample size
After central review of pathology and immunophenotyping of 159 cases, one hundred fifteen patients diagnosed with ALAL were included in this analysis. No sample size calculation was performed. Given the rare nature of the diagnosis understudy, we collected as many samples as possible available to include in our analysis. This sample size is sufficient to provide an overview of common genomic profile of ALAL and to allow further exploration into specific hypothesis based investigations.
Data exclusions Reasons for exclusion included insufficient myeloid antigens (19 cases), insufficient material for diagnosis or genomic analysis (8 cases), insufficient T-ALL antigens (6 cases), insufficient B-ALL antigens (6 cases), cases with translocations detected that reclassified disease as ALL or AML (5 cases). These exclusions were all pre-established and based simply on our stated objectives to study a World Health Organization defined Acute Leukemia of Ambiguous Lineage.
Replication
No replication of genomic analysis was performed in analysis Randomization Nothing to disclose. This is not an intervention study, so randomization is not applicable.
Blinding
Nothing to disclose. This is not an intervention study, so blinding is not applicable.
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